GleamWall
中文EN

JBIO Jade Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1798749 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY44.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-51.4%
ROA-47.4%
ROIC (approx.)-55.4%
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio16.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$30.82M$50.06M$36.05M$28.54M$22.01M$22.55M$20.02M$17.57M
SG&A expense$8.82M$8.85M$7.39M$6.44M$5.39M$5.23M$3.36M$2.41M
Operating income-$39.64M-$58.92M-$43.45M-$34.98M-$27.40M-$27.78M-$23.38M-$19.98M
Pretax income-$35.05M-$55.75M-$40.35M-$31.87M-$25.18M-$32.13M-$38.17M—
Income tax$10,000$15,000$16,000$58,000$0$0—$0
Net income-$35.05M-$55.77M-$40.37M-$31.93M-$25.18M-$32.13M-$38.17M-$30.11M
EBITDA-$39.62M-$58.91M-$43.44M-$34.97M-$27.39M-$27.78M-$23.38M-$19.98M
EPS (basic)-0.42-0.76-0.57—-0.48-0.86-12.10—
EPS (diluted)-0.42-0.76-0.57—-0.48-0.86-12.10—
Weighted avg. shares (diluted)71.76M61.05M57.78M—39.58M28.43M3.16M—
Balance sheet
Cash & equivalents$80.39M$107.25M$55.09M$88.44M$50.11M$220.94M$44.22M$69.39M
Short-term investments$395.32M$353.95M$256.21M$247.72M$148.80M—$31.99M$0
Current assets$485.56M$471.25M$318.52M$348.82M$201.36M$222.98M$77.37M$69.65M
PP&E, net$136,000$144,000$157,000$170,000$176,000$147,000$2,000$0
Total assets$486.39M$472.11M$319.43M$349.78M$202.45M$223.97M$77.53M$72.80M
Current liabilities$30.29M$31.57M$22.29M$16.54M$22.36M$21.62M$2.42M$12.00M
Total liabilities$30.89M$32.20M$22.97M$17.26M$23.10M$22.41M$2.49M$119.60M
Shareholders' equity$455.50M$439.92M$296.46M$332.52M$179.35M$201.56M-$83.51M-$46.80M
Shares outstanding67.08M63.56M49.35M49.32M32.63M32.63M28.99M3.67M
Cash flow statement
Operating cash flow-$28.91M-$43.66M-$24.08M-$33.65M-$22.12M-$36.53M-$18.76M-$15.81M
Capital expenditure———$3,000$57,000———
Free cash flow———-$33.65M-$22.18M———
Investing cash flow-$42.30M-$97.63M-$8.47M-$98.16M-$148.71M-$12.99M$12.85M$13.13M
Financing cash flow$44.35M$193.52M-$795,000$170.16M$0$191.31M-$700,000-$2.77M
Depreciation & amortization$16,000$9,000$9,000$9,000$12,000$1,000$4,000$8,000
Stock-based compensation$7.07M$13.61M$7.41M$9.40M$4.29M$3.90M$2.42M$1.23M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.